|
Stock Options - Additional Information (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2013
|
Mar. 31, 2012
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Sep. 30, 2011
Minimum
|
Sep. 30, 2011
Maximum
|
Sep. 30, 2011
Axo Gen Plan
|
Dec. 31, 2012
Axo Gen Plan
|
Dec. 31, 2011
Axo Gen Plan
|
Sep. 27, 2011
Axo Gen Plan
|
Dec. 31, 2012
Axo Gen Plan
Minimum
|
Dec. 31, 2012
Axo Gen Plan
Maximum
|
Sep. 27, 2011
Employees
|
Sep. 27, 2011
Director
|
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||||||||||||
| Issuance of shares | 18,144,658 | 2,750,000 | ||||||||||||
| Issuance of shares under AxoGen Plan | 2,300,000 | |||||||||||||
| Shares vested percentage | 12.50% | 25.00% | ||||||||||||
| Vested period, Description | Every six months over a four-year period | |||||||||||||
| Vesting Period | 1 year | |||||||||||||
| Options issued to consultants vest over the service period | 3 years | 10 years | ||||||||||||
| Options term range | P7Y | P10Y | ||||||||||||
| Stock-based compensation expense | $ 259,912 | $ 157,860 | $ 495,077 | $ 250,044 | ||||||||||
| Average fair value of options granted | $ 2.99 | $ 0.42 | ||||||||||||
| Intrinsic value of options exercised | 173,000 | 190,000 | ||||||||||||
| Intrinsic value of options outstanding | 1,126,000 | 288,000 | ||||||||||||
| Intrinsic value of options exercisable | 391,000 | 0 | ||||||||||||
| Common stock ratio | 0.03727336 | 0.03727336 | ||||||||||||
| Incremental cost | 19,769 | 38,521 | ||||||||||||
| Total future stock compensation expense related to nonvested awards | $ 1,437,000 | $ 1,405,000 | ||||||||||||
| Weighted average period | 3 years 15 days | |||||||||||||
| Stock options granted | 153,000 | 267,576 | 1,141,952 | |||||||||||